We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Abdelhamid Sabaa
Jul 21, 2015
Yes I would recommend Docetaxel with ADT, threr is 20 months survival advantage of this regime over ADT alone
Vedantham Srinivasan, MD
Jul 21, 2015
agree
david ballingall
Jul 21, 2015
our experience with early docetaxel has not been as favourable as in the trial findings.
abdullah Al-Jaser
Jul 23, 2015
considering the age of the patient , would you consider radiotheraby with ADT
Abdelhamid Sabaa
Jul 23, 2015
Radiotherapy in this setting has no survival advantage it will improve local control
Abdelhamid Sabaa
Jul 23, 2015
Radiotherapy in this setting has no survival advantage it will improve local control
Houssein Elhajj
Aug 16, 2015
the CHARTED study shows survival benefit mostly in patient with high burden metastatic disease (4 bone lesions or visceral metastasis) when addding docetaxel to ADT. For this patient , following what we used to do would be appropriate waiting for more studies confirming the benefit of adding Docetaxel to ADT for such patients. Docetaxel is not without side effects, and it will be there with other hormonal manipulation when the patient will develop CRPC.
J8LXSS9YBD27191 J8LXSS9YBD27191
Aug 27, 2015
I think this case is not appropiate docetaxel because the patient doesnt have the criteria for ecog 3805, ADT plus radiotherapy is the best option
Nick Antoniou
May 10, 2016
.i think iwould be better for this patient to start abiraterone of course with continuation of ADT..
afshan asghar rasheed
Oct 30, 2017
This patient doesn't fit for CHAARTED trial. only single bony mets at L4. Now there is data for oligometastatic disease treatment as curative intent in many malignancies including prostatic ca but not phase 3 trials. I would give local treatment of both areas with continuation of ADT for 2-3 YEARS AS HIGH RISK DISEASE.
Abdelhamid Sabaa
Oct 30, 2017
The stampede trial had shown benefit in both high and low burden metastatic disease
Mar 29, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Abdelhamid Sabaa
Jul 21, 2015
Vedantham Srinivasan, MD
Jul 21, 2015
david ballingall
Jul 21, 2015
abdullah Al-Jaser
Jul 23, 2015
Abdelhamid Sabaa
Jul 23, 2015
Abdelhamid Sabaa
Jul 23, 2015
Houssein Elhajj
Aug 16, 2015
J8LXSS9YBD27191 J8LXSS9YBD27191
Aug 27, 2015
Nick Antoniou
May 10, 2016
afshan asghar rasheed
Oct 30, 2017
Abdelhamid Sabaa
Oct 30, 2017
Mar 29, 2024
Pending Moderator approval.